Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs MBG 453 (Primary) ; PDR 001
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 17 May 2017 Planned End Date changed from 8 Oct 2018 to 8 Oct 2019.
- 10 Feb 2017 Planned End Date changed from 1 Oct 2018 to 8 Oct 2018.